Merck's antiviral pill molnupiravir up for evaluation

2021-10-19

An FDA advisory panel meeting has been scheduled for Nov. 30 to evaluate Merck's antiviral pill molnupiravir, developed in partnership with Ridgeback Biotherapeutics, to treat mild-to-moderate COVID-19. Should the panel back its approval, the oral pill would be used in recently diagnosed COVID-19 patients at high risk for developing severe illness, becoming hospitalized or dying from a coronavirus infection.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.